Given the diversity of p53 mutants in human cancers, it would be useful to understand the overall matrix that dictates immune responses mediated by the family of TLR proteins within the tumor microenvironment, consequences of various agonists and the impact of specific p53 mutant or WT proteins [14] following p53 activating treatments. This evidence concerns the gene TP53 and neoplasm.